Healthcare Industry News: Allergan
News Release - January 4, 2007
Inspire Announces Dry Eye Program UpdateDURHAM, N.C.--(HSMN NewsFeed)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH ) announced today an update in its dry eye program.
Inspire provided additional information to the U.S. Food and Drug Administration (FDA) in November 2006 related to Prolacria(TM) (the proposed U.S. trade name for diquafosol tetrasodium ophthalmic solution 2%). Inspire has been granted a meeting with the FDA to continue discussions regarding Inspire's dry eye clinical program and expects to provide an update on this program by the end of February 2007.
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis and allergic rhinitis. Inspire's U.S. specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. For more information, visit www.inspirepharm.com.
The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Specifically, the anticipated timing of Inspire's update regarding the meeting granted with the FDA with respect to Inspire's dry eye clinical program is a forward-looking statement involving risks and uncertainties. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. The FDA may request that the meeting it has granted regarding Inspire's dry eye clinical program be rescheduled. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.
Source: Inspire Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.